Yeon Hee Park, MD, of the Samsung Medical Center, discusses phase II study findings that showed exemestane plus palbociclib with ovarian suppression improved progression-free survival compared with capecitabine in premenopausal estrogen receptor–positive metastatic breast cancer (Abstract 1007).
Neeraj Agarwal, MD, of Huntsman Cancer Institute, University of Utah Health Care, and Thomas W. Flaig, MD, of the University of Colorado, discuss phase II fi...
Brian C. Baumann, MD, of Washington University School of Medicine, discusses study findings suggesting postoperative radiotherapy may be an option for patients with locally advance...
Sagar Lonial, MD, of Winship Cancer Institute of Emory University, discusses the potentially practice-changing phase III findings showing that lenalidomide substantially delayed pr...
Panagiotis A. Konstantinopoulos, MD, PhD, of Dana-Farber Cancer Institute, discusses his phase II study on the response to avelumab in microsatellite-stable and -instable rec...
Toni K. Choueiri, MD, and Sarah Abou Alaiwi, MD, both of Dana-Farber Cancer Institute, discuss the association of polybromo-associated BAF-type mutations ...
